The multi-center clinical study will investigate the combination of Sofosbuvir and Ribavirin in children between ages 3 and 17. The combined drug therapy has shown 90 percent to 100 percent cure rate in adult patients, according to the report. Dr. Teckman hopes to discover similar results in pediatric patients.
“A lot of times studies for children don’t get approved. The exciting part with our study is that the medication has already been tested in adults, and we are moving rapidly to test in children,” said Dr. Teckman.
More articles on gastroenterology:
Drug therapy for celiac disease?
FDA grants tentative approval of UCERIS for ulcerative colitis
Antidepressants may increase GI bleeding risk
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
